3 6 Ke·2026-01-08 08:10Group 1: Market Outlook - Goldman Sachs predicts that Chinese stocks will be supported by artificial intelligence and policy measures, with the MSCI China Index expected to rise by 20% by the end of 2026, and the CSI 300 Index projected to increase by 12% to 5200 points [1] - As of the first trading day of 2026, the CSI 300 Index has already risen by 3.5%, reaching a four-year high, while the MSCI China Index has increased by approximately 3.6%, outperforming the S&P 500 [1] Group 2: Earnings-Driven Growth - The core argument of Goldman Sachs' report is that returns in 2026 will be primarily driven by earnings growth, supported by artificial intelligence, "going global" strategies, and anti-involution policies [2] - Five major capital flows are expected to support the market: net southbound capital inflows potentially reaching a record $200 billion; domestic asset reallocation bringing about 3 trillion RMB into the stock market; total dividends and buybacks nearing 4 trillion RMB; global active funds possibly increasing their allocation to Chinese stocks; and IPO financing exceeding $100 billion [2] Group 3: Investment Logic - On a macro level, Goldman Sachs has raised its forecast for China's real GDP growth in 2026, citing resilient exports as a key driver, with a trend towards diversification and quality improvement in export destinations [4] - The report indicates that the valuation of the MSCI China Index and CSI 300 has recovered to mid-cycle levels, with forward P/E ratios of 12.4x and 14.5x, respectively, around or slightly above the 10-year average [4] Group 4: Sector and Company Insights - Goldman Sachs expects the TMT sector (technology, media, and telecommunications) to have the highest earnings growth forecast at approximately 20%, driven by AI-related revenue growth and increased capital expenditures [5] - The firm holds an "overweight" view on several sectors, including technology hardware, media/entertainment, internet retail, materials, and insurance, benefiting from various supportive factors [5] - A list of ten leading Chinese companies comparable to the "Big Seven" in the U.S. stock market includes Tencent, Alibaba, CATL, Xiaomi, BYD, Meituan, NetEase, Hengrui Medicine, and Trip.com, with a total market capitalization of $1.7 trillion, accounting for 40% of the MSCI China Index [6]